CHD患者治疗前后血清cTnI、NPY和PGMP检测的临床意义  

Clinical Relevance of Determination the Changes of Serum cTnI,NPY and PGMP Contents After Treatment in Patients with Coronary Heart Diseases

作　　者：葛恒松 马超 吴开霞 

机构地区：[1]江苏省沐阳县人民医院,223600

出　　处：《放射免疫学杂志》2011年第6期637-639,共3页Journal of Radioimmanology

摘　　要：目的:探讨冠心病(CHD)患者治疗前后血清肌钙蛋白I(cTnI)、神经肽Y(NPY)和血小板α-颗粒膜蛋白(PGMP)水平的变化及临床意义。方法:应用放射免疫分析和生化法测定了41例CHD患者血清cTnI、NPY和PGMP含量,并与35名正常健康人作比较。结果:CHD患者在治疗前血清cTnI、NPY和PGMP含量均非常显著地高于正常人组(P<0.01),经治疗6个月后cTnI、NPY水平与正常人组比较无显著性差异(P>0.05),而PGMP水平与正常人组比较仍有显著性差异(P<0.05)。结论:CHD的发生、发展与血清cTnI、NPY和PGMP水平密切相关。Objective To explore the clinical significance of changes of serum cTnI,NPY and PGMP levels in patients with coronary heart diseases after treatment.Methods Serum NPY,PGMP（with RIA）,serum cTnI（with Biochemistry） levels were measured in 41 patients with coronary heart diseases both before and after treatment as well as in 35 normal controls.Results Before treatment,serum cTnI,NPY and PGMP levels were significantly higher than those in controls（P0.01）,after treatment for 6 months the serum cTnI,NPY levels in the patients were not much different than those in the controls（P0.05）,but serum PGMP level remained prominently higher（P0.05）.Conclusion Pathogenesis and progress of CHD,might be closely related to serum cTnI,NPY and PGMP levels.

关 键 词：冠心病 肌钙蛋白I 神经肽Y 血小板Α-颗粒膜蛋白 

分 类 号：R542.22[医药卫生—心血管疾病]